The findings of the study were presented in an oral abstract presentation at the Annual Conference on Retroviruses and Opportunistic Infections (CROI 2019) in Seattle, Washington.
The 48-week results of the Antiretroviral Therapy as Long-Acting Suppression (ATLAS) study indicate that the regimen of monthly injectable cabotegravir/rilpivirine is noninferior to continued 3-drug oral antiretroviral (ART) therapy in adults with virologically suppressed HIV-1 infections.
The findings of the study were presented in an oral abstract presentation at the Annual Conference on Retroviruses and Opportunistic Infections (CROI 2019) in Seattle, Washington. Contagion® spoke exclusively to Susan Swindells, MBBS, who presented the findings at the meeting.
“The study was partnered by a study called FLAIR, which was a similar design in patients who were just starting anti-HIV therapy," said Dr Swindells, an investigator on the study. "They had very similar results: high levels of suppressions in both arms, patients liked it, and both studies went extremely well.”
ATLAS was a phase 3, open-label, multicenter study, which enrolled 616 participants who had HIV-1 RNA <50 c/mL for > 6 months without virologic failure on oral ART regimens of either 2 nucleoside reverse transcriptase inhibitors plus 1 integrase strand transfer inhibitor (NRTI + ISTI), non-nucleoside reverse transcriptase inhibitors (NNRTI), or a protease inhibitor (PI).
A version of this article was originally published by Contagion. Visit ContagionLive.com to view the full article.